哈里斯称，欧盟与美国协议“明确规定”药品关税上限为15%

Core Points - The article discusses the announcement by U.S. President Donald Trump regarding a 100% tariff on pharmaceutical products starting October 1, unless companies build manufacturing plants in the U.S. [1] - Simon Harris, the Irish Deputy Prime Minister, emphasized that a joint statement from the EU and the U.S. on August 21 clearly sets a cap of 15% on any new tariffs imposed on pharmaceutical exports from the EU to the U.S. [1] - Harris mentioned ongoing discussions with U.S. Commerce Secretary Howard Lutnick about expanding the list of products exempt from the 15% baseline tariff rate. [1] Summary by Categories U.S. Tariff Policy - President Trump announced a 100% tariff on pharmaceutical products effective October 1, contingent on U.S. manufacturing [1] - The tariff policy aims to incentivize pharmaceutical companies to establish production facilities in the U.S. [1] EU-U.S. Relations - The EU and U.S. joint statement from August 21 specifies that any new tariffs on EU pharmaceutical exports will be capped at 15% [1] - This agreement is seen as a framework for future trade relations between the EU and the U.S. regarding pharmaceuticals [1] Discussions and Negotiations - Simon Harris is engaging with U.S. officials to explore the potential for expanding the list of products that could be exempt from the 15% tariff [1] - The discussions indicate a collaborative approach to address the implications of the tariff policy on both sides [1]